BioStem Technologies, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from BioStem Technologies, Inc.'s yearly results (2021–2024), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 19.2 times. Higher than 97% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 94% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 92% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2024). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$131Over the last 3 years, every $100 of reported profit came with $131 of operating cash.
Lower than 64% of Healthcare companies in United States.
Self-Funding Ratio
19.2×Over the last 3 years its own operating cash covered its investment spending (capex) 19.2 times.
Higher than 97% of Healthcare companies in United States.
Cash Locked Ratio
$5For every $100 of sales, $5 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $29 from others' credit three years earlier.
Less money tied up than 86% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$11Sales grew 6,853% in 3 years; of every extra $100 of sales, $11 became extra profit.
Lower than 57% of Healthcare companies in United States.
Asset Productivity Ratio
+6853% / +5155%In 3 years sales changed by +6853% while total assets changed by +5155%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
6.2×Debt due within a year is covered 6.2 times by its yearly operating cash.
Higher than 81% of Healthcare companies in United States.
Cash Cushion Ratio
+59%Cash, after subtracting all debt, equals 59% of its market value (net cash).
Higher than 80% of Healthcare companies in United States.
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 94% of Healthcare companies in United States.
Tangible Net Worth Ratio
99%Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 92% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
BioStem Technologies, Inc. owes $0.43 for every $1 it owns. BioStem Technologies, Inc. returned to profit in the year to Dec 2024, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2024.
P/E ratio
1.9Investors pay $1.9 for every $1 of BioStem Technologies, Inc.'s yearly profit, lower than 91% of Healthcare companies in United States.
P/B ratio
1.12The share price is 1.12 times BioStem Technologies, Inc.'s book value per share, lower than 76% of Healthcare companies in United States.
Market cap
$31 MThe total market value of all of BioStem Technologies, Inc.'s shares at today's price (share price × number of shares), smaller than 79% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$28 MWhat BioStem Technologies, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.48Net worth divided by the number of shares. The share price of $1.66 is 1.1 times this, which is the P/B above.
Return on equity (ROE)
-74.7%BioStem Technologies, Inc. lost 74.7% of its shareholders' money over the last year, lower than 63% of Healthcare companies in United States.
Owes vs Owns
0.43×BioStem Technologies, Inc. owes $0.43 for every $1 it owns (low), higher than 51% of Healthcare companies in United States.
Dividend yield
NoneBioStem Technologies, Inc. does not currently pay a dividend.
Revenue growth
+1709%Revenue rose 1709% in the year to Dec 2024, and grew 311% a year on average over 3 years.
Profit growth
Back to profitBioStem Technologies, Inc. returned to profit in the year to Dec 2024, after a loss the year before.
Profit margin
10.6%BioStem Technologies, Inc. keeps $11 of every $100 of revenue as net profit.
Cash quality
0.8×Cash from BioStem Technologies, Inc.'s business was 0.8× its reported profit in the year to Dec 2024 — less cash came in than the profit reported.
Interest cover
53.1×BioStem Technologies, Inc.'s operating profit covered its interest costs 53.1 times in the year to Dec 2024.
Cash vs debt
Net cashBioStem Technologies, Inc. held $18 M more cash than debt (net cash) at Dec 2024.
Questions
What is BioStem Technologies, Inc.'s P/E ratio?
Investors pay $1.9 for every $1 of BioStem Technologies, Inc.'s yearly profit, lower than 91% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For BioStem Technologies, Inc.: $31 M ÷ $28 M (30 Jun 2026) = 1.1.
What is BioStem Technologies, Inc.'s return on equity?
BioStem Technologies, Inc. lost 74.7% of its shareholders' money over the last year, lower than 63% of Healthcare companies in United States.
How much does BioStem Technologies, Inc. owe compared with what it owns?
BioStem Technologies, Inc. owes $0.43 for every $1 it owns (low), higher than 51% of Healthcare companies in United States.
Does BioStem Technologies, Inc. pay a dividend?
No. BioStem Technologies, Inc. does not currently pay a dividend.
Is BioStem Technologies, Inc.'s revenue growing?
Revenue rose 1709% in the year to Dec 2024, and grew 311% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.